---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015299"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:58:43.631716+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Voyager Q3 net loss narrows to $9.0M; new Novartis capsid license; VY7523 SAD data H1 2025

## Summary
- Q3 collaboration revenue $24.6M (up from $4.6M YoY); net loss $9.0M vs $25.9M.
- Licensed TRACER capsid to Novartis for undisclosed rare neurologic target; $15M upfront, up to $305M milestones.
- Neurocrine partnership selected 3rd development candidate, triggering $3M milestone.
- VY7523 anti-tau antibody SAD trial enrollment complete; top-line safety/PK data expected H1 2025.
- Cash $345.4M at Sep 30; plus $18M received in Oct; runway into 2027.

## SEC filing metadata
- accession: 0001558370-24-015299
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837024015299/0001558370-24-015299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837024015299/vygr-20241112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015299
- JSON: https://secwatch.observer/filing/0001558370-24-015299.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015299.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.